Latest News and Press Releases

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...

Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...

Noah Medical to share field results, deliver interactive simulations and host multiple events for its Galaxy System at AABIP 2024

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...

Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...

New York , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The global endoscopy devices market size is projected to grow at a CAGR of over 5% from 2024 to 2036. The market is expected to garner a revenue of USD...

Community Regional Medical Center is the First in California to Offer Next Generation Robotic Bronchoscopy for Early Diagnosis and Treatment of Lung Cancer